Drug Use During Sex and Its Impact on Taking PrEP (Pre-Exposure Prophylaxis) : CONSUME

The Use of Chemsex (Drug Use in a Sexual Context) Among MSM (Men Who Have Sex With Men) and Transgender People in France, Whether or Not Taking PrEP, and Its Impact on PrEP Adherence

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04709016

Acronym

CONSUME

Enrollment

100

Registered

2021-01-14

Start date

2021-03-18

Completion date

2022-03-25

Last updated

2022-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Dependence

Keywords

Chemsex, PrEP

Brief summary

This is a cross-sectional, single-center observational study conducted from October 2020 to March 2021 in Ile de France at the infectious disease of CHU Bichat (PrEP and CeGIDD(Free Center for Information, Screening and Diagnosis of Infections by Human Immunodeficiency Viruses, Viral Hepatitis and Sexually Transmitted Infections) consultation). It concerns adult subjects of male or transgender sex, of MSM (men having sex with men) or bi-sexual orientation. The data are collected by self-questionnaire evaluating the consumption of Chemsex (drug use in a sexual context) over the last 12 months, the existence or not of addiction treatment, the history of STIs (sexually transmitted infections) and adherence to PrEP (for subjects taking PrEP) during the last sexual intercourse (ANRS questionnaire, used in the PREVENIR study).

Interventions

BEHAVIORALself-questionnaire

self-questionnaire assessing Chemsex's (drug use in a sexual context) consumption over the last 12 months

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age\> 18 * male or transgender * MSM or bi-sexual orientation * adult consultant at Bichat Hospital (CeGIDD or PrEP consultation) * adult with a Smartphone (online self-questionnaire)

Exclusion criteria

* For the group taking PrEP: adult taking PrEP for less than 3 months * Refusal of participation

Design outcomes

Primary

Measure	Time frame
compare in an MSM and transgender population, the use of Chemsex depending on whether or not PrEP is taken	inclusion

Secondary

Measure	Time frame
Reported adherence to PrEP	inclusion
The existence or not of psychological comorbidity and the existence of addictological care	inclusion
The number of sexually transmitted infections at inclusion	inclusion

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026